Lantern Pharma (LTRN): מכפיל P/E עתידי

The projected P/E value for Lantern Pharma Inc. (LTRN) on the GURU.Markets terminal linear chart is based on the RADR AI platform, which matches drugs to patient genetics. Panna Sharma's team efficiently manages capital and adheres to trial timelines. The value 0.00 captures the metric level, while demand for oncology therapy remains independent of market cycles and is determined solely by biological data.

To build a defensive portfolio, fundamental screening utilizes the company's 12-month forward P/E, which compares current market capitalization with expected net income for the following year to assess investment attractiveness. In the case of Lantern Pharma Inc. (LTRN), the trend of this metric reflects the market value of the RADR AI platform and its patents, allowing investors to determine the optimal entry point for the asset.